Increased early rejection rate after conversion from tacrolimus in kidney and pancreas transplantation

Journal of the Pancreas

Volumn 3, Issue 2, 2002, Pages 49-53

  Barone, Gary W ^a   Ketel, Beverley L ^a   Abul Ezz, Sameh R ^a   Lightfoot, Meredith L ^a  

^a UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

Author keywords

Drug toxicity; Graft rejection; Immunosuppressive agents

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; CYCLOSPORIN A; INSULIN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; TACROLIMUS; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; DIABETIC NEPHROPATHY; DIALYSIS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAFT REJECTION; GRAFT SURVIVAL; HEMOLYTIC UREMIC SYNDROME; HUMAN; HYPERGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY BIOPSY; KIDNEY DISEASE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; PLASMAPHERESIS; RECIPIENT; RETROSPECTIVE STUDY; CHEMICALLY INDUCED DISORDER; CHRONIC KIDNEY FAILURE; DRUG TOLERANCE; METABOLISM; METHODOLOGY; SALVAGE THERAPY; SURVIVAL RATE;

ADULT; CYCLOSPORINE; DIABETES MELLITUS, TYPE 1; DRUG TOLERANCE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; PANCREAS TRANSPLANTATION; RETROSPECTIVE STUDIES; SALVAGE THERAPY; SURVIVAL RATE; TACROLIMUS;

EID: 0036514968     PISSN: 15908577     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (7)

1. Stratta RF, Tailor RJ, Gill IS. Pancreas transplantation: a managed cure approach to diabetes. Curr Probl Surg 1996; 33:709-808. [AN 96400020]
2. Stegall MD, Simon M, Wachs ME, Chan L, Nolan C, Kam I. Mycophenolate mofetil decreases rejection in simultaneous pancreas-kidney transplantation when combined with tacrolimus or cyclosporine. Transplantation 1997; 64:1695-700. [AN 98082867]
3. Peddi VR, Kamath S, Munda R, Demmy AM, Alexander JW, First MR. Use of tacrolimus eliminates acute rejection as a major complication following simultaneous kidney and pancreas transplantation. Clin Transplant 1998; 12:401-5. [AN 99004216]
4. Bruce DS, Woodle KA, Newell KA, Millis JM, Cronin DC, Loss GE, et al. Tacrolimus/mycophenolate provides superior immunosuppression relative to neoral/mycophenolate in synchronous pancreas-kidney transplantation. Transplant Proc 1998; 30:1538-40. [AN 98300254]
5. Gruessner RWG, Burke GW, Stratta R, Sollinger H, Benedetti E, Marsh C, et al. A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 1996; 61:261-73. [AN 96166734]
6. Gruessner RWG, Bartlett ST, Burke GW, Stock PG. Suggested guidelines for the use of tacrolimus in pancreas/kidney transplantation. Clin Transplant 1998; 12:260-2. [AN 98306488]
7. Kaufman DB, Leventhal JR, Stuart J, Abecasses MM, Fryer JP, Stuart FP. Mycophenolate mofetil and tacrolimus as primary maintenance immunosuppression in simultaneous pancreas-kidney transplantation: initial experience in 50 consecutive cases. Transplantation 1999; 67:586-93. [AN 99168580]